Peters, T. L.
Patil, T. http://orcid.org/0000-0003-4389-1010
Le, A. T.
Davies, K. D.
Brzeskiewicz, P. M.
Nijmeh, H.
Bao, L.
Camidge, D. R.
Aisner, D. L.
Doebele, R. C. http://orcid.org/0000-0001-6728-6857
Funding for this research was provided by:
Specialized Program of Research Excellence grant from the NCI for the University of Colorado in Lung Cancer Research
National Institutes of Health under Ruth L. Kirschstein National Research Service Award University of Colorado Lung Head and Neck Cancer Research
Article History
Received: 8 June 2020
Accepted: 22 September 2021
First Online: 12 October 2021
Competing interest
: K.D.D. received sponsored travel from ArcherDX. D.R.C. received honoraria from and institutional support for clinical trials from Pfizer. R.C.D. serves on the advisory board of Rain Therapeutics, Blueprint Medicines, Anchiano, Green Peptide, Genentech, Bayer, AstraZeneca; has intellectual property licensing with Rain Therapeutics, Foundation Medicine, Abbott Molecular, Black Diamond, Pearl River, and Voronoi; and has stock ownership in Rain Therapeutics. No other authors have any competing interests to disclose.